US university psychiatrist loses chairmanship over drug company payments

BMJ 2009; 338 doi: 10.1136/bmj.a3188 (Published 6 January 2009)
Cite this as: BMJ 2009;338:a3188

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Janice Hopkins Tanne
  1. 1New York

    Charles Nemeroff, a psychiatrist and expert in depression and mood and anxiety disorders, has lost his post as chairman of the department of psychiatry and behavioural sciences at Emory University in Atlanta, Georgia, because of payments from drug companies that he had not disclosed.

    In October, Dr Nemeroff, who had chaired the department for 17 years, temporarily stepped down after the Senate finance committee found that he had received payments from GlaxoSmithKline and other companies but had not reported them to the university or to the National Institutes of Health as required. Emory then set up a new conflict of interest office (BMJ 2008;337:a2200).

    In a statement on 23 December, Emory said that Dr Nemeroff “will remain in the department …

    Access to the full text of this article requires a subscription or payment

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    THIS WEEK'S POLL